Literature DB >> 9395358

Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation.

A V Cope1, C Sabin, A Burroughs, K Rolles, P D Griffiths, V C Emery.   

Abstract

Longitudinal analysis of 162 liver transplant recipients identified 51 patients who were viremic. Virus load was determined in 47 of these patients using quantitative-competitive polymerase chain reaction. Peak virus load was significantly higher in 20 symptomatic patients than 27 asymptomatic patients (P < .0001). Elevated virus load, donor seropositivity, and total methylprednisolone dosage were risk factors for human cytomegalovirus (HCMV) disease (odds ratio [OR], 2.22/0.25 log10 increase in virus load, P = .001; OR, 4.11, P = .05; OR, 1.30/1-g increment in methylprednisolone, P = .01). Methylprednisolone and virus load were independent risk factors in a multivariate analysis (OR, 2.70/1-g increase, P = .003; OR, 1.61/0.25 log10 increase, P = .03, respectively). Virus loads of 10(4.75)-10(5.25) genomes/mL of blood were associated with an increased disease probability; the latter was shifted to lower virus loads with increasing quantities of methylprednisolone. These data illustrate the central role of virus load in HCMV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395358     DOI: 10.1086/514145

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation.

Authors:  C Aitken; W Barrett-Muir; C Millar; K Templeton; J Thomas; F Sheridan; D Jeffries; M Yaqoob; J Breuer
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma.

Authors:  A M Caliendo; R Schuurman; B Yen-Lieberman; S A Spector; J Andersen; R Manjiry; C Crumpacker; N S Lurain; A Erice
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

3.  Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation.

Authors:  A Weinberg; T N Hodges; S Li; G Cai; M R Zamora
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 4.  Is cytomegalovirus viraemia a useful tool in managing CMV disease?

Authors:  J R Deayton
Journal:  Sex Transm Infect       Date:  2000-10       Impact factor: 3.519

5.  Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients.

Authors:  A M Caliendo; K St George; S Y Kao; J Allega; B H Tan; R LaFontaine; L Bui; C R Rinaldo
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

6.  Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis.

Authors:  Roland R Regoes; E Frances Bowen; Alethea V Cope; Dehila Gor; Aycan F Hassan-Walker; H Grant Prentice; Margaret A Johnson; Paul Sweny; Andrew K Burroughs; Paul D Griffiths; Sebastian Bonhoeffer; Vincent C Emery
Journal:  Proc Biol Sci       Date:  2006-08-07       Impact factor: 5.349

7.  Choice of Study Populations for Vaccines.

Authors:  Paul Griffiths; Brenna Hughes
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

8.  The dynamics of human cytomegalovirus replication in vivo.

Authors:  V C Emery; A V Cope; E F Bowen; D Gor; P D Griffiths
Journal:  J Exp Med       Date:  1999-07-19       Impact factor: 14.307

9.  [Esophagitis during immunosuppression].

Authors:  F Moosig; W L Gross
Journal:  Z Rheumatol       Date:  2012-06       Impact factor: 1.372

Review 10.  Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.

Authors:  Raymund R Razonable; Randall T Hayden
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.